Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...

Fate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Fate Therapeutics (NASDAQ:FATE – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at Wedbush ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Looking ahead, ...

SAN DIEGO — SAN DIEGO — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $47.7 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 40 cents ...